Pfizer CEO, under fire, will do ‘whatever it takes’ to grow
Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including further cost cuts, as he seeks to fend off allegations of mismanagement from activist investor Starboard Value LP.
Pfizer CEO: The activist investors are 'too late'
Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the first time on Tuesday.
Pfizer Results May Temper Efforts for Shakeup Demanded by Activist Investor
Pfizer beat third-quarter profit and sales forecasts and raised its guidance on strong sales of its COVID-19 treatment.
Pfizer Exceeds Wall Street’s Q3 Expectations Amid Activist Investor Pressure
CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer reported that third-quarter revenue and adjusted profit beat the analysts’ consensus.
Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure
Pfizer ( PFE) raised its full-year guidance by $1.5 billion and posted strong third quarter earnings Tuesday. The company now expects between $61 billion and $64 billion in revenue for the year and raised its outlook for adjusted earnings to $2.75 to $2.95 per share.
Pfizer CEO defends turnaround strategy as activist pressures management
By Michael Erman and Bhanvi Satija (Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it reported a higher-than-expected profit due to strong sales of COVID-19 treatment Paxlovid.
Pfizer CEO Defends Record Against Activist Attack
Pfizer shares have performed abysmally in recent years, as the company has failed to win investor confidence ahead of a wave of patent expirations coming by the end of the decade.
Pfizer CEO Albert Bourla goes one-on-one with Jim Cramer
Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk quarterly results, what's in the pipeline, ...
devdiscourse17h
Pfizer's Strategic Pivot: Navigating Challenges Amid Investor Pressure
Pfizer CEO Albert Bourla addresses Wall Street, defending the drugmaker's turnaround strategy amidst pressure from activist ...
Pfizer's Oncology Triumphs Keep Investors Hooked Amid Market Volatility
Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...
Pfizer CEO says he welcomes good ideas as Starboard ups pressure on company
Pfizer reported an earnings beat Tuesday morning and raised its full-year outlook, seeing strength in sales of its Covid ...
protothema.gr1d
Albert Bourla: The rehabilitation of the Pfizer strongman in 74 pages
Albert Bourla linked Pfizer ‘s name with the containment effort of the COVID-19 pandemic and this is the piece of history that belongs to him definitively, objectively and beyond any objection or ...
Why Pfizer Stock Is Lower After a Beat-and-Raise Quarter
Pfizer stock is down Tuesday even after the drugmaker reported higher-than-expected Q3 earnings and raised its full-year ...
pharmaphorum4h
Pfizer rebuffs Starboard criticism as it raises forecasts
Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist ...
Pfizer’s guidance bump will not heal deeper wounds
Strip out the Covid product gains and Pfizer’s predicament is unchanged. It is struggling to convince investors there is life ...